Perspective Therapeutics Inc. - Asset Resilience Ratio
Perspective Therapeutics Inc. (CATX) has an Asset Resilience Ratio of 52.82% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Perspective Therapeutics Inc. (CATX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Perspective Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See shareholders equity of Perspective Therapeutics Inc. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Perspective Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CATX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $216.96 Million | 52.82% |
| Total Liquid Assets | $216.96 Million | 52.82% |
Asset Resilience Insights
- Very High Liquidity: Perspective Therapeutics Inc. maintains exceptional liquid asset reserves at 52.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Perspective Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Perspective Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Envoy Medical Inc.
NASDAQ:COCH |
Medical Devices | 0.53% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Perspective Therapeutics Inc. (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Perspective Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.74% | $114.11 Million | $266.97 Million | -5.73pp |
| 2024-12-31 | 48.47% | $165.34 Million | $341.10 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $97.89 Million | -- |
| 2023-06-30 | 39.19% | $22.76 Million | $58.09 Million | 0.00pp |
| 2022-12-31 | 39.19% | $22.76 Million | $58.09 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $64.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $64.44 Million | -- |
| 2021-06-30 | 0.00% | $0.00 | $70.42 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $15.51 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $9.42 Million | -- |
| 2018-12-31 | 8.76% | $825.00K | $9.42 Million | -2.31pp |
| 2018-06-30 | 11.07% | $825.00K | $7.46 Million | -13.70pp |
| 2017-12-31 | 24.77% | $3.04 Million | $12.27 Million | 0.00pp |
| 2017-06-30 | 24.77% | $3.04 Million | $12.27 Million | +12.36pp |
| 2016-12-31 | 12.41% | $2.25 Million | $18.10 Million | 0.00pp |
| 2016-06-30 | 12.41% | $2.25 Million | $18.10 Million | -28.29pp |
| 2015-12-31 | 40.70% | $9.36 Million | $23.00 Million | 0.00pp |
| 2015-06-30 | 40.70% | $9.36 Million | $23.00 Million | +3.02pp |
| 2014-12-31 | 37.68% | $10.00 Million | $26.55 Million | 0.00pp |
| 2014-06-30 | 37.68% | $10.00 Million | $26.55 Million | +23.37pp |
| 2009-12-31 | 14.31% | $1.68 Million | $11.74 Million | 0.00pp |
| 2009-06-30 | 14.31% | $1.68 Million | $11.74 Million | -6.61pp |
| 2008-12-31 | 20.92% | $3.73 Million | $17.81 Million | 0.00pp |
| 2008-06-30 | 20.92% | $3.73 Million | $17.81 Million | -17.21pp |
| 2007-12-31 | 38.13% | $9.94 Million | $26.08 Million | 0.00pp |
| 2007-06-30 | 38.13% | $9.94 Million | $26.08 Million | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more